LONDON--AstraZeneca PLC (AZN.LN) said Friday it got approval for ZS-9, its drug against hyperkalaemia, from the committee for medicinal products for human use of the European medicines agency.

Hyperkalaemia is a condition characterized by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases.

Shares at 1245 GMT down 22 pence, or 0.5%, at 4578.5 pence valuing the company at GBP57.93 billion.

-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

February 24, 2017 08:02 ET (13:02 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more AstraZeneca Charts.